AR093247A1 - Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo - Google Patents
Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismoInfo
- Publication number
- AR093247A1 AR093247A1 ARP130103867A ARP130103867A AR093247A1 AR 093247 A1 AR093247 A1 AR 093247A1 AR P130103867 A ARP130103867 A AR P130103867A AR P130103867 A ARP130103867 A AR P130103867A AR 093247 A1 AR093247 A1 AR 093247A1
- Authority
- AR
- Argentina
- Prior art keywords
- symptoms associated
- neurodegenerative disease
- salts
- mental illness
- impulsive
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 5
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 5
- 208000020016 psychiatric disease Diseases 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 abstract 8
- 230000003542 behavioural effect Effects 0.000 abstract 4
- 238000011321 prophylaxis Methods 0.000 abstract 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- -1 4-benzo [b] thiophene- 4-yl-piperazin-1-yl Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
Abstract
La presente se refiere a un agente profiláctico y/o terapéutico para los síntomas conductuales y psicológicos asociados con enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental, que contiene 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi)-1H-quinolin-2-ona o una de sus sales como un ingrediente activo. Reivindicación 1: Un método para la profilaxis y/o el tratamiento de síntomas conductuales y psicológicos asociados con enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental, caracterizado porque comprende la administración de 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi}-1H-quinolin-2-ona o una de sus sales en una cantidad profilática o terapéuticamente efectiva a un paciente que necesita la profilaxis y/o el tratamiento de síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental. Reivindicación 51: Una composición farmacéutica para usar en la profilaxis y/o el tratamiento de síntomas conductuales y psicológicos asociados con enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental, caracterizado porque comprende 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi)-1H-quinolin-2-ona o una de sus sales como un ingrediente activo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718305P | 2012-10-25 | 2012-10-25 | |
| US201361782467P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093247A1 true AR093247A1 (es) | 2015-05-27 |
Family
ID=49585556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103867A AR093247A1 (es) | 2012-10-25 | 2013-10-24 | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20150272946A1 (es) |
| EP (2) | EP2911670A1 (es) |
| JP (5) | JP6329140B2 (es) |
| KR (1) | KR102245016B1 (es) |
| CN (4) | CN108578408A (es) |
| AR (1) | AR093247A1 (es) |
| AU (1) | AU2013335613B2 (es) |
| BR (1) | BR112015008759A2 (es) |
| CA (1) | CA2889196C (es) |
| EA (1) | EA201590808A1 (es) |
| HK (1) | HK1212609A1 (es) |
| IL (1) | IL238402B (es) |
| JO (2) | JOP20210047A1 (es) |
| MX (1) | MX371279B (es) |
| MY (1) | MY180185A (es) |
| NZ (1) | NZ708321A (es) |
| PH (1) | PH12015500925B1 (es) |
| SG (2) | SG10201702828TA (es) |
| TW (1) | TWI643620B (es) |
| UA (1) | UA116549C2 (es) |
| WO (1) | WO2014065437A1 (es) |
| ZA (1) | ZA201503640B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1558582T3 (pl) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| TR201805216T4 (en) | 2008-10-28 | 2018-06-21 | Arena Pharm Inc | COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| AU2015250611A1 (en) * | 2014-04-22 | 2016-11-24 | H. Lundbeck A/S | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| JP2018502157A (ja) * | 2015-01-12 | 2018-01-25 | レビバ ファーマシューティカルズ，インコーポレイティド | アルツハイマー病の治療方法 |
| WO2016115150A1 (en) * | 2015-01-12 | 2016-07-21 | Reviva Pharmaceuticals Inc. | Methods for treating psychosis associated with parkinson's disease |
| KR20180022792A (ko) | 2015-06-12 | 2018-03-06 | 엑소반트 사이언시즈 게엠베하 | 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체 |
| AU2016291673A1 (en) * | 2015-07-15 | 2018-01-25 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| CN105175401A (zh) * | 2015-10-16 | 2015-12-23 | 北京康立生医药技术开发有限公司 | 一种依匹哌唑的制备方法 |
| CN105541819B (zh) * | 2016-02-04 | 2018-09-14 | 浙江永宁药业股份有限公司 | 一种依匹唑派的制备方法及其中间体和中间体的制备方法 |
| CA3047451A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| JP7149287B2 (ja) | 2016-12-20 | 2022-10-06 | エルテーエス ローマン テラピー－ジステーメ アーゲー | アセナピンおよびポリシロキサンまたはポリイソブチレンを含有する経皮治療システム |
| EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| BR112020011189A2 (pt) | 2017-12-05 | 2020-11-17 | Sunovion Pharmaceuticals Inc. | misturas não racêmicas e usos das mesmas |
| WO2019113084A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| EP3501506B1 (en) | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US11160758B2 (en) | 2019-06-04 | 2021-11-02 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| WO2021029020A1 (ja) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | 経口医薬組成物 |
| CN116113412A (zh) * | 2020-06-24 | 2023-05-12 | 国立大学法人北海道大学 | 血液脑脊髓屏障保护剂 |
| CN112137994B (zh) * | 2020-09-15 | 2022-10-14 | 中山大学 | 小分子化合物在制备抗丝状病毒药物中的应用 |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| CN115429753B (zh) * | 2021-06-02 | 2024-08-06 | 山东百诺医药股份有限公司 | 布瑞哌唑口服混悬液 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| AR085840A1 (es) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| EP2822136B1 (en) * | 2013-07-03 | 2018-08-29 | Siemens Aktiengesellschaft | Method and arrangement for transferring electrical power for subsea applications |
-
2012
- 2012-10-25 JO JOP/2021/0047A patent/JOP20210047A1/ar unknown
-
2013
- 2013-10-24 UA UAA201505106A patent/UA116549C2/uk unknown
- 2013-10-24 TW TW102138482A patent/TWI643620B/zh active
- 2013-10-24 WO PCT/JP2013/079480 patent/WO2014065437A1/en active Application Filing
- 2013-10-24 NZ NZ708321A patent/NZ708321A/en unknown
- 2013-10-24 CN CN201810366157.4A patent/CN108578408A/zh active Pending
- 2013-10-24 EP EP13792110.2A patent/EP2911670A1/en not_active Withdrawn
- 2013-10-24 CN CN202210498926.2A patent/CN114712360A/zh active Pending
- 2013-10-24 AR ARP130103867A patent/AR093247A1/es unknown
- 2013-10-24 MY MYPI2015701327A patent/MY180185A/en unknown
- 2013-10-24 SG SG10201702828TA patent/SG10201702828TA/en unknown
- 2013-10-24 US US14/438,335 patent/US20150272946A1/en not_active Abandoned
- 2013-10-24 BR BR112015008759A patent/BR112015008759A2/pt not_active Application Discontinuation
- 2013-10-24 EP EP21159914.7A patent/EP3848033A1/en active Pending
- 2013-10-24 CN CN201380055961.6A patent/CN104755082A/zh active Pending
- 2013-10-24 JP JP2015521734A patent/JP6329140B2/ja active Active
- 2013-10-24 MX MX2015005174A patent/MX371279B/es active IP Right Grant
- 2013-10-24 AU AU2013335613A patent/AU2013335613B2/en active Active
- 2013-10-24 CA CA2889196A patent/CA2889196C/en active Active
- 2013-10-24 CN CN202011339120.6A patent/CN112402421A/zh active Pending
- 2013-10-24 EA EA201590808A patent/EA201590808A1/ru unknown
- 2013-10-24 KR KR1020157013570A patent/KR102245016B1/ko active IP Right Grant
- 2013-10-24 SG SG11201503152TA patent/SG11201503152TA/en unknown
- 2013-10-24 JO JOP/2013/0313A patent/JOP20130313B1/ar active
-
2015
- 2015-04-21 IL IL238402A patent/IL238402B/en active IP Right Grant
- 2015-04-24 PH PH12015500925A patent/PH12015500925B1/en unknown
- 2015-05-22 ZA ZA2015/03640A patent/ZA201503640B/en unknown
-
2016
- 2016-01-19 HK HK16100569.3A patent/HK1212609A1/zh unknown
-
2017
- 2017-03-28 US US15/471,429 patent/US20170258787A1/en not_active Abandoned
-
2018
- 2018-03-29 JP JP2018065319A patent/JP2018138555A/ja active Pending
-
2019
- 2019-06-28 US US16/456,334 patent/US20190314367A1/en not_active Abandoned
- 2019-10-29 JP JP2019195831A patent/JP2020045345A/ja active Pending
-
2021
- 2021-07-19 JP JP2021118416A patent/JP2021181448A/ja active Pending
-
2022
- 2022-07-21 US US17/869,993 patent/US20220370442A1/en active Pending
-
2023
- 2023-05-30 JP JP2023088455A patent/JP2023123441A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
| CO7141411A2 (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CR20150326A (es) | Inhibidores de autotaxina | |
| CO7190242A2 (es) | Moduladores del transporte nuclear y usos de los mismos | |
| CR20160200A (es) | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
| BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
| CO6710926A2 (es) | Compuestos de n-heteroarilo | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CR20150637A (es) | Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral | |
| AR114032A2 (es) | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma | |
| ECSP14013200A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| DOP2015000071A (es) | Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |